#United States #Precision Medicine #Carlsbad #Tyra Biosciences #TYRA-300

Tyra Biosciences Reports Q1 2025 Financial Highlights

Tyra Biosciences, Inc. (Nasdaq: TYRA), a cutting-edge clinical-stage biotechnology company, has disclosed its financial results for the first quarter of 2025, alongside updates highlighting significant clinical advancements in their therapeutic portfolio. The company focuses on precision medicines targeting pivotal opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, which has implications across various domains of oncology and genetic disorders.

Key Developments and Clinical Initiatives

Tyra's CEO, Todd Harris, has conveyed the organization's commitment for 2025 to get clinical therapies into the hands of patients more effectively. Progress on the TYRA-300 program continues to advance, particularly in treating pediatric achondroplasia (ACH) and intermediate-risk non-muscle invasive bladder cancer (NMIBC).

Clinical Trials Summary:

• - BEACH301 Study of TYRA-300: Designed for pediatric patients aged 3 to 10, this Phase 2 multicenter trial is now open for enrollment, focusing on those with open growth plates. The aim is to evaluate response dynamics in children, both treatment-naïve and those previously treated, using a variety of dose levels.
• - SURF302 Study of TYRA-300: This open-label Phase 2 study aims to assess the drug’s efficacy among 90 participants with FGFR3-altered lower-grade NMIBC. Initial participants will be randomized into two dosing cohorts to reveal complete response rates over three months, providing critical insights into treatment optimization.
• - SURF431 Study of TYRA-430: A milestone achieved with the first patient dosing in this Phase 1 trial for hepatocellular carcinoma (HCC) explores TYRA-430's role in treating advanced cancers with specific genetic alterations.

Preclinical results concerning TYRA-300 have been recently published, showing promising outcomes in promoting bone growth in both FGFR3-driven and wild-type mouse models. This information is critical as it reinforces the efficacy of TYRA-300 in treating disorders linked to bone morphology, enhancing the understanding of FGFR3 functions.

Financial Performance Review:

As of March 31, 2025, Tyra reported cash, cash equivalents, and marketable securities amounting to $318.9 million, sufficient to sustain operational momentum through at least 2027. R&D expenditures saw an increase, reflecting investments in clinical operations and personnel. Despite this growth trajectory, the net loss ballooned to $28.1 million in Q1 2025, compared to the previous year’s loss of $18.2 million, driven by escalating clinical trial costs.

Outlook and Future Initiatives

Looking ahead, Tyra Biosciences is poised on the brink of several critical milestones:

• - Commencement of dosing children with ACH in the BEACH301 trial in Q2 2025.
• - Initiation of patient dosing for IR NMIBC in the SURF302 trial, also anticipated in Q2 2025.

The company’s lead precision medicine program, TYRA-300, seeks to position itself at the forefront of innovations in treating skeletal dysplasia and cancers through targeted therapy models that leverage Tyra's proprietary SNÅP platform for drug discovery.

About Tyra Biosciences
Founded to satisfy a significant gap in the treatment of both genetic and cancerous ailments, Tyra Biosciences continues developing solutions with its next-generation biotechnology. With TYRA-300, TYRA-200, and TYRA-430, the pipeline aims to disrupt existing treatment paradigms through specific targeting of FGFR signaling pathways. As Tyra advances its initiatives, it remains aligned with its mission to create impactful therapies grounded in rigorous scientific investigation. Follow Tyra’s progress via their updates at tyra.bio.

Through steady advancement and strategic operational focus, Tyra Biosciences exemplifies the innovative spirit needed in today’s biotechnology landscape, positioning itself as a thought leader in the convergence of precision medicine and patient-centric therapeutics.